ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

ALZN Alzamend Neuro Inc

0.7721
-0.0779 (-9.16%)
Apr 16 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 116,809
Bid Price 0.73
Ask Price 0.8449
News -
Day High 0.8801

Low
0.74

52 Week Range

High
11.91

Day Low 0.741
Company Name Stock Ticker Symbol Market Type
Alzamend Neuro Inc ALZN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.0779 -9.16% 0.7721 00:00:03
Open Price Low Price High Price Close Price Prev Close
0.8562 0.741 0.8801 0.74105 0.85
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
484 116,809 $ 0.7862921 $ 91,846 - 0.74 - 11.91
Last Trade Time Type Quantity Stock Price Currency
18:59:25 formt 100 $ 0.7721 USD

Alzamend Neuro Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
5.27M 7.12M - 0 -14.88M -2.09 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Alzamend Neuro News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ALZN Message Board. Create One! See More Posts on ALZN Message Board See More Message Board Posts

Historical ALZN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.880.930.7410.880050724,995-0.1079-12.26%
1 Month0.931.10170.7410.942398645,640-0.1579-16.98%
3 Months0.89991.290.741.0255,421-0.1278-14.20%
6 Months3.123.29850.741.48123,915-2.35-75.25%
1 Year8.809511.910.744.41154,877-8.04-91.24%
3 Years435.00503.250.7442.011,236,287-434.23-99.82%
5 Years435.00503.250.7442.011,236,287-434.23-99.82%

Alzamend Neuro Description

Alzamend Neuro Inc is an early clinical stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

Your Recent History

Delayed Upgrade Clock